Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

NCT05216497 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT05216497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
Lead sponsor
Valenta Pharm JSC
Phase
Phase 3
Overall status
Completed
Start date
October 6, 2021
Completion date
April 25, 2022
Enrollment
233 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19